Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded by research analysts at Evercore ISI from an “in-line” rating to an “outperform” rating in a report issued on Monday, MarketBeat reports.
A number of other analysts have also recently weighed in on the stock. BidaskClub cut shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday. Credit Suisse Group restated an “outperform” rating and issued a $147.00 price objective on shares of Alexion Pharmaceuticals in a research note on Thursday, January 18th. Raymond James Financial restated an “outperform” rating and issued a $130.00 price objective (down from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. UBS Group cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research note on Thursday, January 4th. Finally, Robert W. Baird upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price objective for the company in a research note on Monday, December 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $153.10.
Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded down $3.43 during trading on Monday, hitting $112.72. 2,018,872 shares of the stock were exchanged, compared to its average volume of 1,810,000. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals has a twelve month low of $96.18 and a twelve month high of $149.34. The firm has a market capitalization of $25,180.00, a PE ratio of 50.32, a price-to-earnings-growth ratio of 0.97 and a beta of 1.16.
A number of institutional investors have recently made changes to their positions in ALXN. Valeo Financial Advisors LLC bought a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at $147,000. Dupont Capital Management Corp bought a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at $156,000. BT Investment Management Ltd bought a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at $165,000. Beacon Investment Advisory Services Inc. bought a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at $201,000. Finally, Invictus RG bought a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at $202,000. 94.04% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals (ALXN) Upgraded by Evercore ISI to “Outperform”” was reported by American Banking and Market News and is the property of of American Banking and Market News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/05/alexion-pharmaceuticals-alxn-upgraded-by-evercore-isi-to-outperform.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
